Sesión Inmunoterapia - Dr. Ralph Mosges

Prof. Dr. Paolo Falagiani (1947 – 2011)

1: Liccardi G, Passalacqua G, Salzillo A, Piccolo A, Falagiani P, Russo M,

Canonica GW, D'Amato G. Is sensitization to furry animals an independent allergic

phenotype in nonoccupationally exposed individuals? J Investig Allergol Clin

Immunol. 2011;21(2):137-41. PubMed PMID: 21462804.

2: Petrarca C, Lazzarin F, Pannellini T, Iezzi M, Braga M, Mistrello G, Falagiani

P, Di Giampaolo L, Di Gioacchino M. Monomeric allergoid intragastric

administration induces local and systemic tolerogenic response involving

IL-10-producing CD4(+)CD25(+) T regulatory cells in mice. Int J Immunopathol

Pharmacol. 2010 Oct-Dec;23(4):1021-31. PubMed PMID: 21244752.

3: Marogna M, Massolo A, Colombo F, Isella P, Bruno M, Falagiani P. Children

passive smoking jeopardises the efficacy of standard anti-allergic

pharmacological therapy, while sublingual immunotherapy withstands. Allergol

Immunopathol (Madr). 2011 Mar-Apr;39(2):60-7. Epub 2011 Jan 7. PubMed PMID:

21216083.

4: Marogna M, Colombo F, Cerra C, Bruno M, Massolo A, Canonica GW, Falagiani P,

Passalacqua G. The clinical efficacy of a sublingual monomeric allergoid at

different maintenance doses: a randomized controlled trial. Int J Immunopathol

Pharmacol. 2010 Jul-Sep;23(3):937-45. PubMed PMID: 20943066.

5: Liccardi G, Dente B, Restani P, Senna G, Falagiani P, Ballabio C, D'Amato G.

Respiratory allergy induced by exclusive polysensitization to serum albumins of

furry animals. Eur Ann Allergy Clin Immunol. 2010 Jun;42(3):127-30. PubMed PMID:

20648777.

6: D'Anneo RW, Bruno ME, Falagiani P. Sublingual allergoid immunotherapy: a new

4-day induction phase in patients allergic to house dust mites. Int J

Immunopathol Pharmacol. 2010 Apr-Jun;23(2):553-60. PubMed PMID: 20646350.

7: Leonardi S, Arena A, Bruno ME, Cannaò PM, D'Anneo RW, Falagiani P, Gammeri E,

Mistrello G, Nicolini A, Ricciardi L, Valenti G, Longo R, La Rosa M. Olea

sublingual allergoid immunotherapy administered with two different treatment

regimens. Allergy Asthma Proc. 2010 Mar-Apr;31(2):e25-9. PubMed PMID: 20406589.

8: Minelli M, Schiavino D, Musca F, Bruno ME, Falagiani P, Mistrello G, Riva G,

Braga M, Turi MC, Di Rienzo V, Petrarca C, Schiavone C, Di Gioacchino M. Oral

hyposensitization to nickel induces clinical improvement and a decrease in TH1

and TH2 cytokines in patients with systemic nickel allergy syndrome. Int J

Immunopathol Pharmacol. 2010 Jan-Mar;23(1):193-201. PubMed PMID: 20378005.

9: Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and

tolerability of sublingual monomeric allergoid in tablets given without up-dosing

to pediatric patients with allergic rhinitis and/or asthma due to grass pollen.

Eur Ann Allergy Clin Immunol. 2009 Dec;41(6):177-80. PubMed PMID: 20128231.

10: Burastero SE, Mistrello G, Paolucci C, Breda D, Roncarolo D, Zanotta S,

Falagiani P. Clinical and immunological correlates of pre-co-seasonal sublingual

immunotherapy with birch monomeric allergoid in patients with allergic

rhinoconjunctivitis. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):343-52.

PubMed PMID: 19505388.

11: Di Gioacchino M, Perrone A, Petrarca C, Di Claudio F, Mistrello G, Falagiani

P, Dadorante V, Verna N, Braga M, Ballone E, Cavallucci E. Early cytokine

modulation after the rapid induction phase of sublingual immunotherapy with mite

monomeric allergoids. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):969-76.


12: Liccardi G, Passalacqua G, Falagiani P, Russo M, D'Amato G. The effect of

multiple allergens on histamine release in vivo assessed by skin prick test.

Allergy. 2008 Nov;63(11):1559-60. PubMed PMID: 18925893.

13: Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for

allergic respiratory disease in elderly patients: a retrospective study. Eur Ann

Allergy Clin Immunol. 2008 May;40(1):22-9. PubMed PMID: 18700331.

14: D'Anneo RW, Arena A, Gammeri E, Bruno ME, Falagiani P, Riva G, Leonardi S, La

Rosa M. Parietaria sublingual allergoid immunotherapy with a co-seasonal

treatment schedule. Allergol Immunopathol (Madr). 2008 Mar-Apr;36(2):79-84.


15: Burastero SE, Mistrello G, Falagiani P, Paolucci C, Breda D, Roncarolo D,

Zanotta S, Monasterolo G, Rossi RE. Effect of sublingual immunotherapy with grass

monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10

production. Ann Allergy Asthma Immunol. 2008 Apr;100(4):343-50. PubMed PMID:

18450120.

16: Falagiani P. Nickel hyposensitization: a literature review. Int J

Immunopathol Pharmacol. 2005 Oct-Dec;18(4 Suppl):3-5. Review. PubMed PMID:

17761097.

17: Mistrello G, Harfi H, Roncarolo D, Kwaasi A, Zanoni D, Falagiani P, Panzani

R. Date palm pollen allergoid: characterization of its chemical-physical and

immunological properties. Int Arch Allergy Immunol. 2008;145(3):224-30. Epub 2007

Oct 3. PubMed PMID: 17914274.

18: Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous

reactions due to ASA-NSAIDs intolerance. Allergol Immunopathol (Madr). 2007

Jul-Aug;35(4):126-9. PubMed PMID: 17663920.

19: Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and

efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up

phase. Eur Ann Allergy Clin Immunol. 2006 Nov;38(9):310-2. PubMed PMID: 17191751.

20: Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML,

Bruno ME, Falagiani P, Riva G. Clinical efficacy and safety of preseasonal

sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic

patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madr).

2006 Sep-Oct;34(5):194-8. PubMed PMID: 17064648.

21: Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of

sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial

hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch

Allergy Immunol. 2007;142(1):70-8. Epub 2006 Oct 2. PubMed PMID: 17016060.

22: Baruffini A, Pisati G, Russello M, Falagiani P. [Occupational allergic

IgE-mediated disease from Boletus edulis: case report]. Med Lav. 2005

Nov-Dec;96(6):507-12. Italian. Erratum in: Med Lav. 2006 Jan-Feb;97(1):87. PubMed

PMID: 16983976.

23: Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I,

Majani G, Falagiani P, Bruno M, Canonica GW. Randomized double-blind controlled

study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due

to mites. Allergy. 2006 Jul;61(7):849-54. PubMed PMID: 16792583.

24: Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O,

Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapy

with Dermatophagoides monomeric allergoid down-regulates allergen-specific

immunoglobulin E and increases both interferon-gamma- and

interleukin-10-production. Clin Exp Allergy. 2006 Mar;36(3):261-72. PubMed PMID:

16499636.

55: Liccardi G, Russo M, Mistrello G, Falagiani P, D'Amato M, D'Amato G.

Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999

Jun;54(6):643-5. PubMed PMID: 10435484.

25: Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P,

Canonica GW, Passalacqua G. Pharmacokinetics of Der p 2 allergen and derived

monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005

Nov;138(3):197-202. Epub 2005 Oct 3. PubMed PMID: 16205097.

26: Passalacqua G, Altrinetti V, Mariani G, Falagiani P, Mistrello G, Brizzolara

R, Canonica GW, Bagnasco M. Pharmacokinetics of radiolabelled Par j 1

administered intranasally to allergic and healthy subjects. Clin Exp Allergy.

2005 Jul;35(7):880-3. PubMed PMID: 16008673.

27: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Why do lipid

transfer protein-hypersensitive patients tolerate bean (and other legumes)? Int

Arch Allergy Immunol. 2005 Jul;137(3):236-40. Epub 2005 Jun 13. PubMed PMID:

15956792.

28: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Detection of novel

latex allergens associated with clinically relevant allergy to plant-derived

foods. J Allergy Clin Immunol. 2005 Jun;115(6):1312-4. PubMed PMID: 15940153.

29: Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of

sublingual immunotherapy with a monomeric allergoid in very young children.

Allergy. 2005 Jan;60(1):133. PubMed PMID: 15575951.

30: Marogna M, Falagiani P, Bruno M, Massolo A, Riva G. The allergic march in

pollinosis: natural history and therapeutic implications. Int Arch Allergy

Immunol. 2004 Dec;135(4):336-42. Epub 2004 Nov 24. PubMed PMID: 15564776.

31: Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, Passalacqua

G. Quantitative assessment of the adherence to sublingual immunotherapy. J

Allergy Clin Immunol. 2004 Jun;113(6):1219-20. PubMed PMID: 15214362.

32: Hilger C, Thill L, Grigioni F, Lehners C, Falagiani P, Ferrara A, Romano C,

Stevens W, Hentges F. IgE antibodies of fish allergic patients cross-react with

frog parvalbumin. Allergy. 2004 Jun;59(6):653-60. PubMed PMID: 15147451.

33: Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy:

lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol.

2003;13(4):228-31. PubMed PMID: 14989110.

34: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Analysis of the heat

stability of lipid transfer protein from apple. J Allergy Clin Immunol. 2003

Nov;112(5):1009-11. PubMed PMID: 14610497.

35: Bagnasco M, Morbelli S, Altrinetti V, Falagiani P, Mariani G, Passalacqua G.

Allergen biodistribution in humans. Chem Immunol Allergy. 2003;82:33-43. Review.


36: Ballero M, Ariu A, Falagiani P. Allergy to Ailanthus altissima (tree of

heaven) pollen. Allergy. 2003 Jun;58(6):532-3. PubMed PMID: 12757458.

37: Mistrello G, Roncarolo D, Zanoni D, Zanotta S, Amato S, Falagiani P, Ariano

R. Allergenic relevance of Cupressus arizonica pollen extract and biological

characterization of the allergoid. Int Arch Allergy Immunol. 2002

Dec;129(4):296-304. PubMed PMID: 12483034.

38: Di Rienzo V, Falagiani P, Frati F, Sensi L, Marcucci F. Unusual IgE-mediated

allergy to fish bait. Allergy. 2002 Sep;57(9):869-70. PubMed PMID: 12169198.

39: Meglio P, Plantamura M, Arabito E, Falagiani P, Torre A, Rossi P. Does SIT to

Der p protect from snail sensitization? Allergy. 2002 Sep;57(9):868-9. PubMed

PMID: 12169197.

40: Tripodi S, Falagiani P, Perinelli T, Dell'Omo F, Cristaldi A. Allergy to

fishing bait. Allergy. 2002 Jul;57(7):653. PubMed PMID: 12100315.

41: Pocobelli D, Del Bono A, Venuti L, Falagiani P, Venuti A. Nasal immunotherapy

at constant dosage: a double-blind, placebo-controlled study in grass-allergic

rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2001;11(2):79-88. PubMed

PMID: 11642577.

42: Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW,

Passalacqua G. Safety of sublingual immunotherapy with monomeric allergoid in

adults: multicenter post-marketing surveillance study. Allergy. 2001

Oct;56(10):989-92. PubMed PMID: 11576079.

43: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. Allergy to

nonspecific lipid transfer proteins in Rosaceae: a comparative study of different

in vivo diagnostic methods. Ann Allergy Asthma Immunol. 2001 Jul;87(1):68-71.


44: Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Mariani G,

Bagnasco M. Sublingual swallow or spit? Allergy. 2001 Jun;56(6):578. PubMed PMID:

11421908.

45: Arena A, Cislaghi C, Falagiani P. Anaphylactic reaction to the ingestion of

raw onion. A case report. Allergol Immunopathol (Madr). 2000 Sep-Oct;28(5):287-9.


46: Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani

P, Mistrello G, Canonica GW, Mariani G. Pharmacokinetics of an allergen and a

monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp

Allergy. 2001 Jan;31(1):54-60. PubMed PMID: 11167951.

47: Angiola Crivellaro M, Senna G, Riva G, Cislaghi C, Falagiani P, Walter

Canonica G, Passalacqua G. Pollen mixtures used as health food may be a harmful

source of allergens. J Investig Allergol Clin Immunol. 2000 Sep-Oct;10(5):310-1.


48: Senna GE, Andri G, Dama AR, Falagiani P, Andri L. Local nasal immunotherapy:

efficacy and tolerability of two different administration schedules in grass

pollen rhinitis. Allergol Immunopathol (Madr). 2000 Jul-Aug;28(4):238-42. PubMed

PMID: 11022271.

49: Corsico R, Falagiani P, Ariano R, Berra D, Biale C, Bonifazi F, Campi P,

Feliziani V, Frenguelli G, Galimberti M, Gallesio MT, Liccardi G, Loreti A,

Marcer G, Marcucci F, Meriggi A, Minelli M, Nardelli R, Nardi G, Negrini CA, Papa

G, Piu G, Pozzan M, D'Ambrosio FP, Riva G. An epidemiological survey on the

allergological importance of some emerging pollens in Italy. J Investig Allergol

Clin Immunol. 2000 May-Jun;10(3):155-61. PubMed PMID: 10923590.

50: Romano C, Ferrara A, Falagiani P. A case of allergy to globe artichoke and

other clinical cases of rare food allergy. J Investig Allergol Clin Immunol. 2000

Mar-Apr;10(2):102-4. PubMed PMID: 10879999.

51: Romano C, Ferrara AM, Cislaghi C, Falagiani P. Food allergy to frog. Allergy.

2000 Jun;55(6):584-5. PubMed PMID: 10858996.

52: Falagiani P. Intranasal immunotherapy. Allergy. 1999;54 Suppl 58:53-5.

Review. PubMed PMID: 10735653.

53: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. True

monosensitivity to a tropical sole. Allergy. 1999 Nov;54(11):1228-9. PubMed PMID:

10604565.

54: Crimi E, Voltolini S, Minale P, Falagiani P. Value of immunoglobulin E

density in predicting nasal and bronchial response to inhaled allergens in

rhinitic and asthmatic subjects with multiple sensitizations. Clin Exp Allergy.

1999 Dec;29(12):1663-70. PubMed PMID: 10594543.

55: Liccardi G, Russo M, Mistrello G, Falagiani P, D'Amato M, D'Amato G.

Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999

Jun;54(6):643-5. PubMed PMID: 10435484.

56: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of

sesame seed-induced anaphylaxis. Allergy. 1999 May;54(5):526-7. PubMed PMID:

10380788.

57: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Cislaghi C, Falagiani P. A

new apple extract. Allergy. 1999 Jan;54(1):87-8. PubMed PMID: 10195370.

58: Roncarolo D, Minale P, Mistrello G, Voltolini S, Falagiani P. Food allergy to

Boletus edulis. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):850-1. PubMed PMID:

9648715.

59: Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW. Local

immunotherapy: pharmacokinetics and efficacy. Allergy. 1998 May;53(5):477-84.

Review. PubMed PMID: 9636806.

60: Mistrello G, Gentili M, Roncarolo D, Antoniotti P, Ottoboni F, Falagiani P.

Dot immunobinding assay for detection of mite antigens in house-dust samples. J

Med Entomol. 1998 Mar;35(2):143-7. PubMed PMID: 9538574.

61: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of

garlic allergy. J Allergy Clin Immunol. 1998 Mar;101(3):427-8. PubMed PMID:

9525465.

62: Pisati G, Baruffini A, Bernabeo F, Falagiani P. Environmental and clinical

study of latex allergy in a textile factory. J Allergy Clin Immunol. 1998

Mar;101(3):327-9. PubMed PMID: 9525447.

63: Coppola V, Veronesi A, Indraccolo S, Calderazzo F, Mion M, Minuzzo S,

Esposito G, Mauro D, Silvestri B, Gallo P, Falagiani P, Amadori A, Chieco-Bianchi

L. Lymphoproliferative disease in human peripheral blood mononuclear

cell-injected SCID mice. IV. Differential activation of human Th1 and Th2

lymphocytes and influence of the atopic status on lymphoma development. J

Immunol. 1998 Mar 1;160(5):2514-22. PubMed PMID: 9498797.

64: Passalacqua G, Albano M, Pronzato C, Riccio AM, Scordamaglia A, Falagiani P,

Canonica GW. Long-term follow-up of nasal immunotherapy to Parietaria: clinical

and local immunological effects. Clin Exp Allergy. 1997 Aug;27(8):904-8. PubMed

PMID: 9291287.

65: Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P,

Mistrello G, Canonica GW. Absorption and distribution kinetics of the major

Parietaria judaica allergen (Par j 1) administered by noninjectable routes in

healthy human beings. J Allergy Clin Immunol. 1997 Jul;100(1):122-9. PubMed PMID:

9257796.

66: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Falagiani P.

Exercise-induced egg anaphylaxis. Allergy. 1997 Jun;52(6):687-9. PubMed PMID:

9226076.

67: Asero R, Mistrello G, Falagiani P. Oral allergy syndrome from pork. Allergy.

1997 Jun;52(6):684-6. PubMed PMID: 9226073.

68: Zardi O, Zardi EM, Falagiani P, Zardi DM, Zardi MC, Barduagni F, Barduagni O.

[Subcutaneous human dirofilariasis]. Pathologica. 1997 Feb;89(1):31-5. Review.

Italian. PubMed PMID: 9312730.

69: Canonica GW, Passalacqua G, Mariani G, Motta C, Bartolomei M, Mistrello G,

Falagiani P, Bagnasco M. Oral routes for immunotherapy: clinical efficacy and

kinetics of the allergen. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf

A M. 1997;(91):56-64; discussion 64-7. Review. PubMed PMID: 9383892.

70: Falagiani P, Mistrello G. Pharmacokinetics of allergens after local

administration. Allergy. 1997;52(33 Suppl):17-21. Review. PubMed PMID: 9188942.

71: Liccardi G, Mistrello G, Noschese P, Falagiani P, D'Amato M, D'Amato G. Oral

allergy syndrome (OAS) in pollinosis patients after eating pistachio nuts: two

cases with two different patterns of onset. Allergy. 1996 Dec;51(12):919-22.


72: D'Amato G, Russo M, Liccardi G, Saggese M, Gentili M, Mistrello G, D'Amato M,

Falagiani P. Comparison between outdoor and indoor airborne allergenic activity.

Ann Allergy Asthma Immunol. 1996 Aug;77(2):147-52. PubMed PMID: 8760781.

73: Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P.

Monomeric chemically modified allergens: immunologic and physicochemical

characterization. Allergy. 1996 Jan;51(1):8-15. PubMed PMID: 8721522.

74: Andri L, Senna G, Betteli C, Givanni S, Andri G, Dimitri G, Falagiani P,

Mezzelani P. Local nasal immunotherapy with extract in powder form is effective

and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol.

1996 Jan;97(1 Pt 1):34-41. PubMed PMID: 8568135.

75: Andri L, Senna G, Andri G, Dama A, Givanni S, Betteli C, Dimitri G, Falagiani

P, Mezzelani P. Local nasal immunotherapy for birch allergic rhinitis with

extract in powder form. Clin Exp Allergy. 1995 Nov;25(11):1092-9. PubMed PMID:

8581842.

76: Mistrello G, Gentili M, Falagiani P, Roncarolo D, Riva G, Tinelli M. Dot

immunobinding assay as a new diagnostic test for human hydatid disease. Immunol

Lett. 1995 Jul-Aug;47(1-2):79-85. PubMed PMID: 8537105.

77: Romano C, Sulotto F, Piolatto G, Ciacco C, Capellaro E, Falagiani P,

Constable DW, Verga A, Scansetti G. Factors related to the development of

sensitization to green coffee and castor bean allergens among coffee workers.

Clin Exp Allergy. 1995 Jul;25(7):643-50. PubMed PMID: 8521183.

78: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in

a coffee-processing factory. Int Arch Allergy Immunol. 1995

May-Jun;107(1-3):443-4. PubMed PMID: 7613207.

79: Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local intranasal

immunotherapy with allergen in powder in atopic patients sensitive to Parietaria

officinalis pollen. J Investig Allergol Clin Immunol. 1995 May-Jun;5(3):126-32.


80: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in

a coffee processing factory. Allergol Immunopathol (Madr). 1995

Jan-Feb;23(1):29-34. PubMed PMID: 7631592.

81: Falagiani P, Mistrello G, Rapisarda G, Festa A, Cislaghi C, Zanoni D.

Evaluation of allergenic potency by REAST inhibition. A new tool for the

standardization of allergenic extracts. J Immunol Methods. 1994 Aug

1;173(2):181-90. PubMed PMID: 8046253.

82: D'Amato G, Gentili M, Russo M, Mistrello G, Saggese M, Liccardi G, Falagiani

P. Detection of Parietaria judaica airborne allergenic activity: comparison

between immunochemical and morphological methods including clinical evaluation.

Clin Exp Allergy. 1994 Jun;24(6):566-74. PubMed PMID: 7922776.

83: Mistrello G, Roncarolo D, Gentili M, Zanoni D, Falagiani P. Modified par j I

allergen from P judaica pollen and its rate of absorption in rats. Immunol Lett.

1994 Apr;40(1):31-6. Erratum in: Immunol Lett 1994 Jul;41(2-3):291. PubMed PMID:

7927511.

84: Costa MA, Colombo P, Izzo V, Kennedy H, Venturella S, Cocchiara R, Mistrello

G, Falagiani P, Geraci D. cDNA cloning, expression and primary structure of Par

jI, a major allergen of Parietaria judaica pollen. FEBS Lett. 1994 Mar

21;341(2-3):182-6. PubMed PMID: 8137937.

85: Panzani RC, Mercier P, Delord Y, Riva G, Falagiani P, Reviron D, Auquier P.

Prevalence of patent and latent atopy among a general normal adult population in

the south east of France by RAST investigation and correlation with circulating

total IgE levels. Allergol Immunopathol (Madr). 1993 Nov-Dec;21(6):211-9. PubMed

PMID: 8160568.

86: Caneva E, Di Gennaro P, Farina F, Orlandi M, Rindone B, Falagiani P.

Synthesis and characterization of a penicillin-poly(L-lysine) which recognizes

human IgE anti-penicillin antibodies. Bioconjug Chem. 1993 Sep-Oct;4(5):309-13.


87: Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal

immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder

extract. J Allergy Clin Immunol. 1993 May;91(5):987-96. PubMed PMID: 8491949.

88: Ariano R, Panzani RC, Falagiani P, Chiapella M, Augeri G. Respiratory allergy

to the pollen of Mercurialis annua (Euphorbiaceae). Ann Allergy. 1993

Mar;70(3):249-54. PubMed PMID: 8452320.

89: Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P.

Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol. 1993

Mar;20(3):489-94. PubMed PMID: 8386767.

90: Panzani RC, Falagiani P, Riva G, Mercier P, Delord. Screening for IgE

mediated allergy among people working in the Marseilles harbour. Allergol

Immunopathol (Madr). 1993 Jan-Feb;21(1):25-9. PubMed PMID: 8328353.

91: Andri L, Senna GE, Betteli C, Givanni S, Andri G, Falagiani P, Lugo G. Local

nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled

study. Allergy. 1992 Aug;47(4 Pt 1):318-23. PubMed PMID: 1443452.

92: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello

G, Sondergaard I. Purification of Phleum pratense pollen extract by

immunoaffinity chromatography and high-performance ion-exchange chromatography. J

Chromatogr. 1991 Jul 12;548(1-2):229-34. PubMed PMID: 1939423.

93: Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P,

Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis

and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T

cells with stable and opposite (type 1 T helper or type 2 T helper) profile of

cytokine production. J Clin Invest. 1991 Jul;88(1):346-50. PubMed PMID: 1829097;

PubMed Central PMCID: PMC296040.

94: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello

G, Sondergaard I. Allergenic fragments in Parietaria judaica pollen extract. J

Chromatogr. 1991 Apr 12;542(2):337-44. PubMed PMID: 1715346.

95: Moscato G, Dellabianca A, Falagiani P, Mistrello G, Rossi G, Rampulla C.

Inhaled furosemide prevents both the bronchoconstriction and the increase in

neutrophil chemotactic activity induced by ultrasonic "fog" of distilled water in

asthmatics. Am Rev Respir Dis. 1991 Mar;143(3):561-6. PubMed PMID: 2001067.

96: Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in

serum after intranasal treatment of normal rabbits with P. judaica extract.

Allergy. 1991 Jan;46(1):52-8. PubMed PMID: 2018209.

97: Falagiani P. Thimerosal in standard antigenic extracts. Contact Dermatitis.

1989 Nov;21(5):354. PubMed PMID: 2620521.

98: Cocchiara R, Locorotondo G, Parlato A, Guarnotta G, Ronchi S, Albeggiani G,

Amoroso S, Falagiani P, Geraci D. Purification of Parj I, a major allergen from

Parietaria, judaica pollen. Int Arch Allergy Appl Immunol. 1989;90(1):84-90.


99: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,

Riva G, Bolzacchini E. Micropreparative-scale enrichment of some allergenic

components of Parietaria pollen extract. J Chromatogr. 1988 Jul 27;446:179-85.


100: Genchi C, Falagiani P, Riva G, Tinelli M, Brunello F, Boero M, Almaviva M.

IgE and IgG antibodies in Toxocara canis infection. A clinical evaluation. Ann

Allergy. 1988 Jul;61(1):43-6. PubMed PMID: 3389570.

101: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,

Riva G, Bolzacchini E. Analysis of allergenic components of a Parietaria judaica

pollen extract by chromatographic methods for the evaluation of purification

procedures. J Chromatogr. 1988 Jul 1;444:209-18. PubMed PMID: 3204131.

102: Bolzacchini E, Di Gregorio G, Nali M, Rindone B, Tollari S, Falagiani P,

Riva G, Crespi G. Purification and molecular weight studies on the components of

a Parietaria pollen extract. Allergy. 1988 Jan;43(1):53-9. PubMed PMID: 3344935.

103: Amoroso S, Cocchiara R, Locorotondo G, Parlato A, Lampiasi N, Albeggiani G,

Falagiani P, Geraci D. Antigens of Euparipha pisana (snail). I. Identification of

allergens by means of in vivo and in vitro analysis. Int Arch Allergy Appl

Immunol. 1988;85(1):69-75. PubMed PMID: 2448245.

104: Tinelli M, Falagiani P, Riva G, Genchi C. RAST and ELISA in three

autochthonous parasitic infections in Italy: toxocariasis, hydatidosis and

fascioliasis. Boll Ist Sieroter Milan. 1987;66(1):38-45. PubMed PMID: 3620121.

105: Sgambato F, Pedicini A, De Rienzo D, Falagiani P. [Inhalation allergy to fly

larva. A clinical case]. Boll Ist Sieroter Milan. 1987;66(5):411-5. Italian.


106: Boner AL, Vallone G, Bennati D, Falagiani P, Gaburro D. Simplified spinhaler

method for antigen-specific bronchoprovocation in children with bronchial asthma.

I. Ann Allergy. 1986 Nov;57(5):363-6. PubMed PMID: 3777536.

107: Brunello F, Falagiani P, Genchi C. Enzyme immunoassay (ELISA) for the

detection of specific IgG antibodies to Toxocara canis ES antigens. Boll Ist

Sieroter Milan. 1986;65(1):54-60. Erratum in: Boll Ist Sieroter Milan

1986;65(5):following 445. PubMed PMID: 3718679.

08: Genchi C, Tinelli M, Brunello F, Falagiani P. Serodiagnosis of ocular

toxocariasis: a comparison of specific IgE and IgG. Trans R Soc Trop Med Hyg.

1986;80(6):993-4. PubMed PMID: 3603652.

109: Falagiani P, Cavallone E, Nali M, Rindone B, Tollari S, Crespi G. Aqueous

size-exclusion analysis of Parietaria pollen extracts. J Chromatogr. 1985 Jun

28;328:425-31. PubMed PMID: 4030974.

An impressively productive scientific mind

Il dosaggio radio-immunologico delle reagine del secreto nasale.

• Boll Soc Ital Biol Sper.

• 1977 Feb 15 ; 53(3):188-92.

• Crifò S, Falagiani P, Filiaci F, Andriani G.

http://www.ncbi.nlm.nih.gov/pubmed/901655

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Crif%C3%B2%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Falagiani%20P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Filiaci%20F%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Andriani%20G%22%5BAuthor%5D

The author of numerous books

Concept of the monomeric allergoid

The novel view on specific

immunotherapy

The Idea:

To combine the advantages of allergoids together with the

sublingual route into a better effective and more safe

Immunotherapy

The first specific sublingual immuntherapy with allergoids available as tablets & drops

Maintained conformation for T-cell-binding

Chemical modification of residual peripheral

aminoacid-sequences Reduced IgE binding affinity

Allergens The unmodified molecule is destroyed

by the attack of enzymes.

Sublingual Allergoides the modified molecule resists to

enzymatic coupling and remains intact.


The novel approach

Allergen extracts are chemically transformed, the Carbamylation, to replace parts of the protein components, and to maintain the molecular dimensions.

Monomerization (Monoid)


1-Reduction of the Allergenicity

2-Maintenance of the Antigenicity

3-Maintenance of the Molecular Dimension

4-Resistance against Enzymatic Digestion

5-Absence of Toxicity

Characterization of the sublingual carbamylated allergoid (Monoid)

Concept Overview

Allergen Type Antigenity Allergenicit

y

Proteine

Structure

Enzymatic

Protection

Monoid Maintained Reduced

(targeted)

Modified,

complex

(„Segments

cut“)

Shown

Native Allergen Maintained Maintained Nativ, complex Not shown

Allergoid

Reduced

(Not

targeted)

Reduced

(targeted) Polymerized Not shown

Allergoid

SLIT

oral

mucosa

gastrointestinal

mucosa

APC Lymphozytes

Lymphatic

system

systemic

circulation

capillaries

clinical

results

Route of action in the oromucosal and gastrointestinal system

Pharmacokinetics

& Immunology

To study the pharmacokinetics

in allergic volunteers

of allergoid sublingual immunotherapy

in oromucosal tablets

Objective

Clin Exp Allergy 2001, 31; 54-60

Pharmacokinetics of an allergen and a monomeric

allergoid for oromucosal immunotherapy


Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,

Falagiani P, Mistrello G, Canonica GW, Mariani G.. Clinical Immunology Service, DIMI, Genoa, Italy

Radiolabelled monomeric allergoid and native allergen, administered to 8

allergic pts and 1 non atopic, were detected by scintigraphic acquisitions.

Plasma radioactivity was measured at different intervals.

Methods

The increased resistance to gastrointestinal enzymatic degradation can explain

the high absorption of the monomeric allergoid and its appearance in the

bloodstream.

The local persistence of the monomeric allergoid and allergen may involve the

mucosal immunity in the mechanism of action of antiallergic vaccination.

Results





Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,

Falagiani P, Mistrello G, Canonica GW, Mariani G.. Clinical Immunology Service, DIMI, Genoa, Italy

Pla

sm

ati

c R

ad

ioacti

vit

y

Hrs after application

Sublingual allergoids

in form of tablets

Native Allergens

in form of tablets

Native Allergens

in liquid solution

I

2

I

5

I

1

I

15

1 -

3 -

5 -

ALLERGO Kinetics





M. Bagnasco et al. Clinical Immunology Service, DIMI, Genoa, Italy

Systemic absorption

Mucosal immunity involvement

Conclusions





M. Bagnasco et al. Clinical Immunology Service, DIMI, Genoa, Italy


Sublingual immunotherapy in Dermatophagoides monomeric

allergoid down-regulates allergen-specific immunoglobulin E

and increases both interferon- and interleukin-10-production.

Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O,

Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy

Objective

Methods

To show the immunological effects of a sublingual carbamylated allergoid.

25 pts: with rhinitis / asthma to Der p1, positive to

anamnesis, prick, RAST, SNPT and MCH.

Protocol: double blind vs placebo. 1,5 years of treatment.

Treated group: 12 Lais Der p1

Placebo group: 13

the sublingual allergoid increases the

production of the cytokines IL-10 & IFN-





L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy

Results

the sublingual allergoid reduces the

production of spezific IgE






Results

Clear immunological effects have been shown under

treatment with a sublingual carbamylated allergoid.






Conclusion

DBPC Trials Results

Sublingual Allergoids

efficacy (subjective data)

• Reduction of symptoms of asthma • Reduction of symptoms of rhinoconjunctivitis • Reduction of symptomatic medication

Results from recent (DBPC) Trials


efficacy (objective data) Efficacy was assessed using objective measurements:

• increase of the provocative dose specifically in nasal provocation test

unspecifically with Metacholine



Safety

The safety of treatment is supported by numerous published clinical studies. The sublingual allergoid, the Monoid, has demonstrated its safety also in patients with Oral Allergy Syndrome (OAS).



Tolerability Tolerability is supported by data from numerous clinical trials



Compliance Compliance, adherence with the treatment is excellent as demonstrated by:

•Pill count in clinical trials. •Repetitive prescription in real life studies.



Allergy, 2000: 55: 1-6

Preseasonal local allergoid immunotherapy to grass pollen

in children: a double-blind, placebo-controlled, randomized

trial

C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, Italy

Material & methods

48 pts: 8 yrs mean age, Rhinoconjunctivitis/Asthma

to Grass. DBPC study. Positive anamnesis,

SPT and RAST. ECP, symptoms, drug score

and Compliance recorded.

Protocol: preseasonal scheduling.

IT treated: 24 Lais Grass.

Drug treated: 20 (4 drop out).

Allergy, 2000: 55: 1-6



trial


Statistically significant differences in

Allergoid SLIT treated group:

Reduced symptom & medication scores in pollen season

Good compliance.

Results

No differences in placebo group.

Reduction of total symptom score during treatment with sublingual allergoids vs Placebo

During the grass pollen season.

sco

re

5 -

I Symptome

NASAL

N S

10 -

15 -

I Symptome

OCULAR

N S p<0.05

I Symptome

BRONCHIAL

I Symptome

TOTAL

p<0.05

I Rescue medication

N S

Allergy, 2000: 55: 1-6



trial


Allergy, 2000: 55: 1-6



trial


The preseasonal course with Lais Grass

as Allergoid SLIT:

is effective in the reduction of respiratory

symptoms of children,

in particular asthma, within 3,5 months

Conclusions

Allergol et Immunopathol 2006; 34 (5): 194 – 198.

Clinical efficacy and safety of preseasonal sublingual

immunotherapy with gras pollen carbamylated allergoid in

rhinitic patients. A double-blind, placebo-controlled study.

Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,

Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal

33 pts: with rhinitis / asthma to Phl p5, positive to


Protocol: double blind vs placebo

Treated group: 17 Lais 3-Gras Mix

Placebo group: 16

Material & Methods







Design







Results

Improvement of the nasal provocation test

Reduction of rhinoconjunctivitis symptoms





A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal

Results Reduction of steroid consumption





A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal

SLIT in gras allergic patients is effective and reduces

single symptoms between 40 - 60 %

and

co-medication (steroids) vs. placebo up to 80%

(at pollen peak)

Conclusions

Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)

Efficacy and safety of oral immunotherapy in respiratory

allergy to Parietaria judaica pollen.

A double blind study

R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy

**Lab. De Recherches, Marseille, France

30 pts: with rhinitis / asthma to Par j, positive to


Protocol: double blind vs placebo. Dec.92 to Jul.95.

Treated group: 15 Lais Par j (1 drop out).

Placebo group: 15

Material & methods







Statistically significant differences in the


Reduced symptoms score (in particular during pollen season).

Reduced medication score.

Increased threshold dose with Allerkin Test.

Increased threshold dose with Methacholine Lofarma.

Results








Hyposensitization with Parietaria pollen as

Allergoid SLIT

is a safe and efficaceous vaccine

which may be used in children and adults.

Conclusions

The Lancet Vol.351 Feb 28, 1998

Randomised controlled trial of local allergoid

immunotherapy on allergic inflammation in

house dust mite - induced rhinoconjunctivitis

G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, Italy

20 pts: per. rhinoconjunctivitis to Der, positive to

anamnesis, prick, RAST and SCPT.

Inflammatory-cells and ICAM-1 and

serum inflam. markers (ECP) recorded.

Protocol: double blind vs placebo. Apr.94 to Mar.96.

Treated group: 10 Lais Der p&f.

Placebo group: 10 (1 drop out).

Material & methods


The monomeric Allergoid SLIT group:

Reduced symptom & medication scores.

Reduced inflammatory infiltration and ICAM-1 expression.

Reduced MPI, the Minimal Persistent Inflammation.

Results







Reduction of inflammation After 24 months of treatment with sublingual allergoids vs Placebo

Demonstrated by conjunctival provocation test

ICA

M 1

I

24 Months

I

T 0

1 -

3 -

N S

p<0.001 E

OS

INO

FIL

E

I

24 Months

I

T 0

1 -

3 -

N S

0.001

NE

UT

RO

FIL

E

I

24 Months

I

T 0

5 -

10 -

N S

0.001






Hyposensitization with Dermatophagoides

as Allergoid SLIT:

l reduces the allergic inflammation

l is safe and clinically effective.

Conclusions






Giornale Italiano di All e Imm Clin, 2000: 10: S-1

Allergen Specific Oromucosal Immunotherapy: Efficacy and

Safety of a Clustered Scheme of

Treatment for Parietaria Respiratory Allergy

S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.Italy

Material & methods

39 pts: Rhinoconjunctivitis / Asthma (50%) to Par.

Positive anamnesis, SPT, PFT and SNPT.

Serum inflam. markers (ECP) recorded.

Symptoms & Drug Score, QoL.

Protocol: clustered treatment according to Data Sheet.

IT treated: 27 Lais Par.

Drug treated: 12 (3 drop out).








Reduced symptom & medication scores.

Improved Quality of Life, assessed by questionnaire.

Good compliance, over 80% .

Results







The Clustered Treatment with Parietaria as

Allergoid SLIT:

l is a suitable treatment when it is too

late to start a conventional scheduling

l is well tolerated and safe.

Conclusions

To study the safety of ultra

rush SLIT with four commercial

products in allergic patients.

Objective

Giorn it Allergol Immunol Clin 2002; 12:221-226

Safety of Ultra Rush (two hours) Sublingual

Swallow Immunotherapy in Allergic Patients

R.E. Rossi, G.Monasterolo*

Allergy Unit, National Health Service, Savigliano, Italy

*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy

Ninety-one allergic patients with rhino-conjunctivitis

and/or asthma.

Prospective observational, 36 months follow-up study.

Maintenance phase from Dec 2001 to Mar 2002.

Subdivided in three groups, one was administered the

sublingual allergoid, the others, injective I.T. and drugs.

Material & Methods







One adverse event, after 300 IR/ml,

disappeared when adjusted at 30 IR.

No adverse events were noted after

administration of the allergoid SLIT.

Results







To evaluate the efficacy, tolerability

and adherence to treatment of

allergoid sublingual immunotherapy

(I.T.), in comparison with injective

I.T. and drugs.

Objective

Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282

Specific Immunotherapy of allergic disease:

A three years prospective observational study

A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, Italy

One hundred and ten allergic patients with rhino-

conjunctivitis and/or asthma.

Subdivided in three groups, one was administered the

sublingual allergoid, the others injective I.T. and drugs.

Prospective, observational, 36 months follow-up study.

Allergens: pollens and House Dust Mite.

Material & Methods



A three years perspective observational study


Sublingual allergoid I.T. was

considered by patients and doctors to

be better than the other two therapies

(p<0.0001) as far as efficacy,

tolerability and patient’s compliance

concern.

Results





Allergoid Sublingual I.T. was

positively appreciated by both

patients and physicians for its

simplicity of use, good efficacy and

the high degree of safety offered.

Conclusions





SLIT with monomeric allergoid

• Effective in rhinoconjunctivitis and asthma

• Impeccable safety also in risk populations

• Perfectly tolerable in adults and children

• Outstanding compliance and adherence

• Internationally accepted by

– The Paul Ehrlich Institute

Thank you for the attention

Paolo Falagiani

1947 - 2011

Health & Medicine

Sesión Inmunoterapia - Dr. Ralph Mosges